Recent News

Most analyses regarding the excess risk of death during the COVID-19 pandemic have relied on summary data. However, a recent study published in the International Journal of Epidemiology instead analyzed individual patient-level data based on medical records from the largest integrated healthcare system in the United States.

This year, experts think the timing of the RSV season will be closer to the pre-pandemic normal, but case numbers will probably be anything but — that is, if people embrace newly available tools to prevent RSV.

Annual spikes in infections from the respiratory syncytial virus — or RSV — are usually so predictable that “you can set your clock” by it, says Yale School of Public Health Associate Professor of Epidemiology (Microbial Diseases) Daniel Weinberger. Normally a cold-weather epidemic, RSV usually spreads among young children, straining hospitals in the Northern Hemisphere as early as late October and lasting until the cold and flu season wanes in spring. The COVID-19 pandemic appears to have upended this rhythm in one country and possibly others.

Yale School of Public Health and Yale Pathology Labs have joined with the Connecticut Department of Public Health to offer free COVID testing in New Haven using the Yale-developed SalivaDirect method.

A new partnership between the state Department of Public Health and the SalivaDirect Initiative of the Yale School of Public Health and Yale Pathology Labs will provide additional COVID-19 testing and lab capacity in the city, officials said Thursday.

Pooled testing allows labs to combine saliva samples from multiple individuals into a single tube and process the batch as a single test. This approach maintains clinical sensitivity while enabling labs to process tests far more quickly.

Investigators funded by Women’s Health Research at Yale have identified significant differences in how the immune systems of women and men respond to the virus that causes COVID-19.

A saliva-based laboratory diagnostic test developed by researchers at the Yale School of Public Health to determine whether someone is infected with the novel coronavirus has been granted an emergency use authorization by the U.S. Food and Drug Administration (FDA).

A research team led by Yale’s Nathan Grubaugh and Anne Wyllie will begin testing select players, coaches, and staff from the NBA teams that have opted into the study, using a testing method they developed, known as SalivaDirect. The results of the study are expected by the end of July and will be shared publicly.